

INSPIRE* Data Corroborates Predictors of FVC Change at Week 72 Observed in CAPACITY



* Trial of Interferon gamma-1b in 826 patients

FIGURE 1

%FVC Change from Baseline in ITT (Pooled PIPF-004 + PIPF-006) vs. "ASCEND Criteria" Subgroup




ITT	Week 48	Week 72
Absolute Δ	3.3%	2.5%
Relative Δ	41.6%	22.8%
P-value	<0.001	0.005

"ASCEND"	Week 48	Week 72
Absolute Δ	6.1%	7.9%
Relative Δ	63.3%	57.0%
P-value	<0.001	<0.001

Solid – pirfenidone
Dashed - placebo

FIGURE 2

%FVC Change from Baseline in PIPF-004 and PIPF-006 in Patients Meeting "ASCEND Criteria"




PIPF-004	Week 48	Week 72
Absolute Δ	7.5%	9.8%
Relative Δ	71.2%	66.5%
P-value	0.007	<0.001

PIPF-006	Week 48	Week 72
Absolute Δ	4.3%	5.7%
Relative Δ	51.7%	44.7%
P-value	<0.001	0.028

Solid – pirfenidone
Dashed - placebo

FIGURE 3

6MWD Change from Baseline in ITT (Pooled PIPF-004 + PIPF-006) vs. "ASCEND Criteria" Subgroup




ITT	Week 48	Week 72
Absolute Δ	19.8 m	24.0 m
Relative Δ	40.5%	31.3%
P-value	0.004	<0.001

"ASCEND"	Week 48	Week 72
Absolute Δ	42.4 m	58.7 m
Relative Δ	64.2%	59.5%
P-value	<0.001	<0.001

Solid – pirfenidone
Dashed - placebo

FIGURE 4

6MWD Change from Baseline in PIPF-004 and PIPF-006 in Patients Meeting "ASCEND Criteria"



PIPF-004	Week 48	Week 72
Absolute Δ	42.6 m	48.8 m
Relative Δ	62.1%	51.8%
P-value	0.005	0.036

PIPF-006	Week 48	Week 72
Absolute Δ	41.5 m	70.4 m
Relative Δ	66.4%	67.5%
P-value	0.002	<0.001

Solid – pirfenidone
Dashed - placebo

FIGURE 5